5th Else-Kröner-Symposium in Würzburg

Else Kröner-Fresenius-Stiftung, Internationales Symposium, Immuntherapie, Andreas Beilhack, Würzburg
The immune system, a tightly knit network of cells, tissues and biochemicals that they secrete, defends our body against fungi, bacteria, viruses, and other invaders. But cancer and some infections often find ways to hide from the immune system or block its ability to fight. The 5th international Else-Kröner-Symposium “Translational Immunology – From Target to Therapy V” took place in Würzburg to exchange the newest research and clinical data on novel approaches to foster the immune system to prevent and treat human diseases. 

This year’s symposium from April 12-13, 2018, was organized by our young physician-scientists in training of the Else-Kröner-Forschungskolleg for Interdisciplinary Translational Immunology. They are ten selected and associated fellows from different medical disciplines (cardiology, dermatology, gynecology, hematology-oncology, internal medicine, urology and nuclear-medicine). On top of their training in their respective medical fields Else-Kröner-fellows participate in a structured program for translational immunological research. As part of their program they are also organizing an annual symposium, “Translational Immunology – From Target to Therapy”. At this event supported by the Else-Kröner-Fresenius-Stiftung there is the opportunity to listen to leaders in translational immunology research from all over the world and to present and discuss their work with these international experts in immunodiagnostics and -therapy.

Else-Kröner-Symposium 2018 - Translational Immunology - Immunotherapy Andreas Beilhack Lab, Würzburg, Germany

Immunotherapy tries to help the immune system recognize cancer or infections as a threat, and attack it. Although many approaches to harness our immune system are investigated two promising types of immunotherapy have entered clinical cancer therapy. One creates a new, individualized treatment for each patient by removing some of the person’s immune cells, altering them genetically to kill cancer and then infusing them back into the bloodstream. Although this treatment has so far been still limited to hematological malignancies, it has resulted in long remissions in a few hundred children and adults with deadly forms of leukemia or lymphoma for whom standard treatments had failed. The second approach, which is now being widely explored in all forms of cancer, involves mass-produced therapeutic antibodies that do not have to be tailored to each patient. These biological drugs foster immune cells to fight cancer by blocking a mechanism — called a checkpoint — that cancer cells abuse to shut down the immune system. Beside immune checkpoints and genetically engineered T cells, the symposium covered many other topics, from autoimmune disease to neuro-immunology.

Again, this year’s Else-Kröner-Symposium provided a great platform to listen to and interact with international leaders in cancer immunotherapy, inflammation, autoimmune and infectious diseases. The list of speakers included Philipp Beckhove (Regensburg), Mark Coles (Oxford), Angus Dalgleish (London), Wilfried Ellmeier (Wien), Manuel Friese (Hamburg), Thomas Gebhardt (Melbourne), Audrey Gérard (Oxford), Michael Hölzel (Bonn), Alexander Kerster (Rehovot), Christopher Klebanoff (New York), Thomas Korn (München), Jens Stein (Bern), Viktor Umansky (Heidelberg), Sjoerd van der Burg (Leiden), Hans van Eenenaam (Nijmegen) and Robert Zeiser (Freiburg). Again this year one physician scientist in training and one PhD researcher were awarded with a poster prize. This year’s awardees are Dr. Tanja Stüber from the Department of Obstetrics and Gynecology and Dr. Duc Dung Le from the Beilhack lab – Congratulations to our young scientists!

Charity Concert for Cancer Research

Forschung hilft! - STIFTUNG FÖRDERUNG Krebsforschung Universität Würzburg, Andreas Beilhack, Hilfe im Kampf gegen Krebs, BenefizkonzertOn March 17th, 2018, the new cancer research foundation Forschung hilft!  (Research helps!) invited to a charity concert by the German Doctors Orchestra in the grand concert hall of the conservatory of Würzburg University.

The wonderful performance started with Carl Maria von Weber’s overture Master of the Spirits. Conducted by Alexander Mottok, Weber’s music shined brightly. The concert eclipsed with Elisabeth Müller’s stellar performance of Camille Saint-Saëns’ impressionistic violin concerto No. 3. Standing ovations after Robert Schumann’s 3rd symphony were rewarded with a special feature of Alexander Mottok’s own composition. – A fine evening indeed!

The German Doctors’ Orchestra was founded in 1989. Its 150 members are predominantly medical doctors of all disciplines but also pharmacists, nurses and medical students. Many of them have a professional musical education. The orchestra consists exclusively of volunteer musicians and are led by Alexander Mottok, a freelance conductor. For more than ten years, the orchestra’s hallmark has been to perform charity concerts at the highest musical level.

The new foundation Forschung hilft! – Research helps! supports promising research projects and extraordinary achievements of scientists at the University of Würzburg, for example through scholarships. Invigorated by the crowdfunding campaign “Your Immune System Becomes Your Weapon Against Cancer”, Würzburg’s foundation “Hilfe im Kampf gegen Krebs” donated €100,000 to the new foundation when it was founded in mid-December 2017. Since then, Forschung hilft! aims to achieve its goals through donations. The Beilhack lab’s research approach has been selected by this charity to propel immunotherapy for cancer treatment.

From Target to Therapy

From April 12th to 13th, 2018 we are organizing the International Else-Kröner-Conference “Translational Immunology – From Target to Therapy V” at the beautiful historical venue of the Juliusspital in Würzburg, Germany.

Else-Kröner-Fresenius-Stiftung, Translational Immunology, From Target to Therapy, Würzburg University Hospital, Andreas BeilhackThe Symposium is organized by the Else-Kröner-fellows of our physician-scientist training program of interdisciplinary translational immunology. Würzburg’s Else-Kröner-fellows are ten selected and associated young physicians from different medical disciplines (cardiology, dermatology, gynecology, hematology, internal medicine, oncology, pathology, urology and pediatrics) who are engaged in a structured translational research training program lead by Prof. Andreas Beilhack and Prof. Jörg Wischhusen. Once a year the fellows organize the conference “Translational Immunology – From Target to Therapy”, where they can present and discuss their work with international guest speakers who are leaders in translational immunology research.

You would like to participate? – Register here!

3D Infect – Immunology Training Course

This week, the Beilhack Lab conducted an intensive training course in immunology for the trainees of our DFG research training group RTG2157 “3D Infect”.
3D Infect, DFG RTG2157, DFG GRK2157, Immunology Training Course 2018, Andreas Beilhack laboratory, Würzburg University Hospital, Tim Steinfatt, Katja Ottmüller

Graduate students of RTG2157 3D Infect at Würzburg University advance and employ 3D human tissue models to investigate host-pathogen interactions. The purpose of these models is to reflect the natural infection site in humans to elucidate the molecular and mechanistic basis for interactions between host and microbes. This week, the Beilhack lab offered an intensive training course in immunology. The course addressed concepts in immunology and immunological methods with an emphasis on multicolor flow cytometry. Katja Ottmüller, Tim Steinfatt and Julia Hartweg provided not only theoretical background to the members of the RTG2157 but also hands-on training in laboratory techniques and in-depth data analysis.

3D Tissue Models for Studying Microbial Infections by Human Pathogens, Andreas Beilhack laboratory Würzburg University Immunology Program

Infectious diseases remain one of the leading causes of death. A clear limitation of studying human pathogens is the lack of relevant infection models. This is particularly true for human pathogens for which no animal reservoir is known. Since simple cell lines, cell culture systems or animals are highly artificial models for human pathogens, the members of the DFG research training group RTG2157 3D Infect aims to develop and apply novel human 3D infection models based on engineered human tissues. In a joint project with the group of Prof. Markus Sauer, the Beilhack lab actively participates in this endeavor. The study of host-pathogen interactions is also in the Beilhack lab’s focus in the interdisciplinary DFG research consortium TRR124 FungiNet and in collaborations within the Center for Infectious Diseases (ZINF) at Würzburg University and with the new Helmholtz Center for RNA-based Infectious Research in Würzburg.

Journal of Clinical Investigation – First joint paper of new GvH-GvL Consortium

A new study lead by Prof. Kai Hildner from Erlangen University identifies BATF-expressing T cells as key players in intestinal acute graft-versus-host disease (GvHD).
DFG Transregio TRR221 GvH-GvL Erlangen-Regensburg-Würzburg, Andreas Beilhack Laboratory Immunology Program, Würzburg University, Germany, Defu Zeng, City of Hope National Medical Center

Alloreactive BATF+ effector memory T cells enhance inflammation by producing GM-CSF and augmenting the infiltration of innate immune cells in the intestinal mucosa. Zeng D, J Clin Invest 2018, © JCI.

Surprisingly, the transcription factor BATF controlled the formation of a distinct IL-7 receptor signaling–responsive GM-CSF+ T cell subset. These newly identified pathologic IL-7RhiGM-CSF+ T cells link IL-7, a cytokine previously mostly associated with T cell reconstitution, to the occurrence of acute GVHD. Furthermore, the study revealed GM-CSF derived from alloreactive T cells as a major driver of systemic and intestinal GvHD. These findings pinpoint the newly identified IL-7R/BATF/GM-CSF axis as a promising therapeutic target to prevent or even treat acute GvHD in patients undergoing allogeneic hematopoietic cell transplantation. 

The new research article by Evelyn Ullrich et al. appeared today in the Journal of Clinical Investigation. The work resulted from a collaboration of an interdisciplinary team comprising several members of our newly founded DFG research consortium TR221 GvH-GvL between the partner universities Erlangen, Regensburg and Würzburg.

Further reading:

Commentary by Prof. Defu Zheng on this article in the Journal of Clinical Investigation.

Link to research article: 

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K. (2018). BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. J Clin Invest. 2018 Jan 29. pii: 89242. doi: 10.1172/JCI89242. [Epub ahead of print]


GvH-GvL consortium kick-off meeting

On January 23rd principal investigators gathered for the inaugural meeting of the new DFG TRR221 collaborative research center on the modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation in Regensburg.

TRR221, DFG, GvH GvL consortium, Regensburg, Erlangen, Würzburg, allogeneic hematopoietic cell transplantation, Wolfgang Herr, Hermann Einsele, Andreas Mackensen, Andreas Beilhack laboratory

Allogeneic hematopoietic cell transplantation is a curative treatment regimen for many patients with leukemia and lymphoma. The new TRR221 consortium connects research teams from the universities of Erlangen, Regensburg and Würzburg to address key challenges of allogeneic hematopoietic cell transplantation. The efficacy of this therapy is mediated by the graft-versus-leukemia (GvL) effect by immune cells of the stem cell donor. However, this desired GvL does not occur to the same degree in all patients to prevent leukemia or lymphoma recurrence after allogeneic hematopoietic cell transplantation. Furthermore, the new forming immune system of the donor can attack healthy organ compartments of the stem cell recipients, an unwanted and often life-threatening immune reaction termed graft-versus-host disease (GvHD). Within the first five years after transplantation, about 60 percent of patients die from GVHD or leukemia.

Our new interdisciplinary research consortium aims to develop innovative immunomodulatory strategies for specifically enhancing the GvL effect and for selective attenuation of GvHD. Our most recent meeting in Regensburg provided the opportunity to elect the board of the consortium, to define the key priorities for the near future, and, importantly, to exchange our most recent research results. A great start for an exciting opportunity to tackle together an unsolved medical problem and to help patients through a concerted research effort.

Science Immunology: New findings on thymus regeneration after damage

A new paper in Science Immunology identified a molecule called BMP4 that plays a key role in the thymus’ extraordinary natural ability to recover from damage. Collaborating with scientists from the Memorial Sloan Kettering Hospital in New York City and the Fred Hutchinson Cancer Research Center in Seattle revealed how BMP4 and thymic endothelial cells enable thymus repair.

Thymus regeneration, transplantation, chemotherapy, irradiation, Memorial Sloan Kettering, Fred Hutchinson Cancer Center, Andreas Beilhack laboratory, Würzburg University Immunology Program

Thymic endothelial cells proved critical for thymic regeneration via their production of bone morphogenetic protein 4 (BMP4). Upon thymus damage, thymic endothelial cells increased their production of BMP4. Endothelial cell-derived BMP4 fostered development, maintenance, and regeneration of thymic epithelial cells. BMP4’s importance on endogenous tissue regeneration offers a potential clinical approach to enhance T cell immunity. Novel treatment regimens based on these findings may promote immune competence in patients undergoing chemo- and radiation therapy.


Read more: 

The Scientist: Researchers Develop a Technique to Regenerate the Mouse Thymus

Medical Press: How the immune system’s key organ regenerates itself


Wertheimer T, Velardi E, Tsai J, Cooper K, Xiao S, Kloss CC, Ottmüller KJ, Mokhtari Z, Brede C, deRoos P, Kinsella S, Palikuqi B, Ginsberg M, Young LF, Kreines F, Lieberman SR, Lazrak A, Guo P, Malard F, Smith OM, Shono Y, Jenq RR, Hanash AM, Nolan DJ, Butler JM, Beilhack A, Manley NR, Rafii S, Dudakov JA, van den Brink MRM. (2018). Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. Sci Immunol 3:19.

Open Research Technician Position

Prof. Dr. Dr. Andreas Beilhack, Universitätsklinikum Würzburg, Experimentelle Stammzelltransplantation, Immunologie Programm Würzburg

In der Arbeitsgruppe für Experimentelle Stammzelltransplantation der Medizinischen Klinik und Poliklinik II des Universitätsklinikums Würzburg ist eine vorerst für ein Jahr befristete


ab Februar 2018 ganztags zu besetzen. 


Thank you for your interest. This position is not available anymore.

Biofabrication – New DFG Research Consortium launched

Scientists from a broad variety of different disciplines join forces to form a new research consortium on biofabrication – to print living cells and tissue structures. Propelling this next generation technology will open entirely new avenues for biomedical research and future therapies.
Biofabrikation, Biofabrication, Bioprinting, Tissue engineering, Würzburg University, Germany, artificial lymph node

“From the Foundations of Biofabrication to Functional Tissue Models” – The new DFG TRR-SFB 225 consortium

The German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) announced that it will fund a Transregional Collaborative Research Center initiated by the three Franconian Universities of Würzburg, Bayreuth and Erlangen. Under the guidance of Prof. Jürgen Groll from Würzburg University, this new research consortium will push the newly emerging field of biofabrication forward.  

The term of our new DFG Collaborative Research Center “Biofabrikation” is designed for a period of twelve years. In the first four-years the consortium aims to investigate basics of biofabrication. The DFG funds this initial period with around ten million Euros to create an internationally leading competence center. 

Read more about the new DFG TRR-SFB 225 consortium “From the Foundations of Biofabrication to Functional Tissue Models”.

New DFG consortium on hematopoietic cell transplantation

The DFG approves the new research consortium SFB TRR221, which focusses on harnessing anti-leukemia mechanisms without the risk of adverse immune reactions.
Graft-versus-Leukemia, Graft-versus-Host disease, Andreas Beilhack, GvHD laboratory, Würzburg University Hospital, Germany, Stanford University

The new DFG  consortium focuses on the modulation of transplant-versus-host and transplant-against-leukemia immune reactions.

Allogeneic hematopoietic stem cell transplantation is the only curative treatment option for many patients with leukemia and lymphoma. Their effectiveness is based on the so-called graft-versus-leukemia (GvL) effect: The transplanted immune cells of the donor form a new functional immune system in the patient to fight the tumor cells. However, the effect is not sufficient in all patients to prevent the return of leukemia or lymphoma. Furthermore, there is often an undesirable effect in which the immune cells of the donor attack healthy tissue of the patient, termed graft-versus-host disease (GvHD). Within the first five years after transplant, approximately 60 percent of patients die as a result of GvHD or the return of the disease.

A newly formed research consortium investigates how desired GvL responses can be separated from unwanted GvH reactions. The German Research Foundation (DFG) will fund the new SFB Transregio TRR221 consortium on the “Modulation of transplant-versus-host and transplant-against-leukemia immune reactions after allogeneic hematopoietic stem cell transplantation.” Under the leadership of Prof. Wolfgang Herr, three Bavarian universities – Erlangen, Regensburg and Würzburg will investigate the immunological mechanisms of blood stem cell transplantation. The teams of our consortium will address the central problems and deficits of allogeneic hematopoietic stem cell transplantation. Consequently we aim to develop immunomodulatory strategies for the specific enhancement of the GvL effect and for the selective attenuation of GvHD. This collective gain of knowledge will result in new treatment concepts. These will be tested outside the DFG TRR221 in clinical studies with the aim of reducing the incidence of morbidity and mortality of allogenic blood stem cell transplantation by promoting the highly effective GvL immune response without associated GvHD. The consortium is planned to operate for 12 years. On November 24, 2017, after a thorough two-step evaluation process, the DFG approved funding for an initial phase of four years. 

DFG Transregio TRR 221 research consortium, GvH-GvL, graft-versus-host disease, graft-versus leukemia reaction, Andreas Beilhack laboratory, Würzburg University Hospital, Wolfgang Herr, Hermann Einsele, Andreas Mackensen

1 2 3 4 6